A late-stage drug development firm specific in oncology and endocrine therapy.

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 research in ovarian tumor at ASCO 2010 Encouraging trend observed in general survival Aeterna Zentaris Inc. , , a late-stage drug development firm specific in oncology and endocrine therapy, today announced that it offered positive efficacy and security data for its doxorubicin targeted conjugate substance, AEZS-108, in ovarian cancer Where can I buy aciclovir tablets? . The demonstration was created by Prof. AEZS-108 is currently in a Phase 2 trial conducted in Europe by the German AGO Research Group , in advanced endometrial and ovarian malignancy, with final results expected by year-end.